CompletedPhase 2NCT04533022
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vicore Pharma AB
- Principal Investigator
- Joanna Porter, MDRespiratory Medicine, University College Hospital
- Intervention
- C21(drug)
- Enrollment
- 52 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2020 – 2024
Study locations (21)
- AMCMET Medical College and Sheth LG General Hospital, Ahmedabad, Gujarat, India
- Unity Hospital, Surat, Gujarat, India
- The Bhatia Hospital, Mumbai, Maharashtra, India
- Grant Government Medical Collage and Sir J.J. Group of Hospitals, Mumbai, Maharashtra, India
- N. K. P. Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India
- Ace Hospital & Research Center, Pune, Maharashtra, India
- Oyster & Pearl Hospitals, Pune, Maharashtra, India
- Hindusthan Hospital, Coimbatore, Tamil Nadu, India
- Jawaharlal Nehru Medical College - Aligarh Muslim University, Aligarh, Uttar Pradesh, India
- Midland Healthcare and Research Centre, Lucknow, Uttar Pradesh, India
- Apollo Spectra Hospitals (Apollo Speciality Hospital Pvt. Ltd.), Kanpur, India
- Clinical Hospital for Emergency Medical Care n.a. N.V. Solovyev, Yaroslavl, Russia
- MNCE City Clinical Hospital, Kharkiv, Ukraine
- Lviv National Medical University, Lviv, Ukraine
- Odessa Regional Hospital, Odesa, Ukraine
- +6 more locations on ClinicalTrials.gov
Collaborators
Orphan Reach Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04533022 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center